Drug Approval | April 22, 2026
US FDA okays Merck's new once-daily HIV pill
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform
By cutting pain crises & boosting haemoglobin
Targets high-growth eye care expansion push
The plant is currently scaling towards a production capacity of nearly 3 million gloves per day
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
The approval, following a positive recommendation from the European Medicines Agency’s CHMP, makes the vaccine valid across all 27 EU member states
Subscribe To Our Newsletter & Stay Updated
